Competition for AstraZeneca’s (LSE: AZN) Soliris (eculizumab) is stepping closer to the market, with developer Amgen (Nasdaq: AMGN), a Californian biotech giant, announcing positive trial results.
The top-line data come from the DAHLIA study, which is testing ABP 959, a biosimilar candidate referencing the blockbuster paroxysmal nocturnal hemoglobinuria (PNH) therapy.
The study met its primary endpoints, demonstrating no clinically-meaningful differences between ABP 959 and Soliris, based on key measures of efficacy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze